Merrill Lynch Cuts Novartis (NVS) To Sell; Bioanalytical Systems (BASI) Sentiment Is 2.67

December 6, 2017 - By Marie Mckinney

Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, other North America, the Pacific Rim, Europe, and internationally. The company has market cap of $22.98 million. It operates in two divisions, Contract Research Services and Research Products. It currently has negative earnings. The Contract Research Services segment offers screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing services.

Among 16 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 4 Sell and 7 Hold. Therefore 31% are positive. Novartis Ag has $110 highest and $7700 lowest target. $93.40’s average target is 12.07% above currents $83.34 stock price. Novartis Ag had 34 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Barclays Capital on Wednesday, October 25 to “Sell”. JP Morgan maintained Novartis AG (NYSE:NVS) on Wednesday, April 19 with “Neutral” rating. Credit Suisse downgraded the stock to “Underperform” rating in Wednesday, July 5 report. The stock of Novartis AG (NYSE:NVS) has “Neutral” rating given on Wednesday, January 11 by Credit Suisse. Cowen & Co maintained it with “Hold” rating and $90.0 target in Friday, October 13 report. The rating was maintained by Leerink Swann on Thursday, June 22 with “Hold”. The rating was downgraded by Morgan Stanley on Tuesday, April 12 to “Underperform”. Goldman Sachs maintained the stock with “Neutral” rating in Thursday, March 23 report. JP Morgan maintained the stock with “Neutral” rating in Friday, March 24 report. The firm earned “Hold” rating on Friday, June 23 by Barclays Capital.

Acadian Asset Management Llc holds 0% of its portfolio in Bioanalytical Systems, Inc. for 12,193 shares. Bank Of America Corp De owns 52 shares or 0% of their US portfolio. Moreover, Barclays Plc has 0% invested in the company for 83 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 24,610 shares.

The stock decreased 2.82% or $0.0808 during the last trading session, reaching $2.7892. About 19,513 shares traded. Bioanalytical Systems, Inc. (BASI) has risen 61.39% since December 6, 2016 and is uptrending. It has outperformed by 44.69% the S&P500.

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company has market cap of $197.53 billion. The companyÂ’s Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. It has a 29.69 P/E ratio. This divisions also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :